Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

Small molecule compounds targeting multiple kinases involved in neoangiogenesis have shown survival benefits in patients with unresectable hepatocellular carcinoma (HCC). Nonetheless, despite the beneficial effects of multikinase inhibitors (MKIs), a lack of boosting adjuvant limits their objective...

Full description

Bibliographic Details
Main Authors: Ke Wang, Pei-Yin Liao, Wei-Chun Chang, Cian-Ru Yang, Yu-Ting Su, Ping-Ching Wu, Yang-Chang Wu, Yao-Ching Hung, Najim Akhtar, Hsueh-Chou Lai, Wen-Lung Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
hepatocellular carcinoma
LDC
linoleate
pazopanib
LAPC
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1281067/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1281067/full

Similar Items